Streetbeat News

ROIV

Roivant Sciences Ltd.

Industry

Biotechnology

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Open

10.72

Mkt cap

7.6B

Volume

High

10.86

P/E Ratio

-10.68

52-wk high

13.05

Low

10.67

Div yield

N/A

52-wk low

9.76

Montes Archimedes Acquisition (ROIV) has been upgraded to a Zacks Rank #2 (Buy) due to growing optimism about its earnings prospects.

Portfolio Pulse from

February 14, 2025 | 6:30 pm

Roivant Sciences Ltd. (ROIV) held its Q3 2024 earnings call, discussing financial performance and future outlook.

Portfolio Pulse from

February 10, 2025 | 5:45 pm

Roivant (Nasdaq: ROIV) reported its Q3 2024 financial results, highlighting significant developments in its clinical pipeline, including new trials for brepocitinib and progress in IMVT-1402 and batoclimab studies. The company also reported strong financials with $5.2 billion in cash and securities.

Portfolio Pulse from

February 10, 2025 | 12:15 pm

Roivant's recent $7.1B sale of Telavant to Roche highlights its potential, but the company's stock has underperformed compared to the S&P 500. While Brepocitinib shows promise for NIU treatment, it faces safety concerns and competition. Mosliciguat could compete with Tyvaso pending Phase 2 results.

Portfolio Pulse from

February 05, 2025 | 5:30 pm

Zest Health has secured $13 million in funding to address unnecessary pharmaceutical spending by focusing on high-touch care for inflammatory skin diseases. The company aims to reduce the overprescription of expensive biologics.

Portfolio Pulse from

February 03, 2025 | 12:15 pm

Roivant (Nasdaq: ROIV) will report its financial results for the third quarter ended December 31, 2024, and provide a business update on February 10, 2025.

Portfolio Pulse from

January 29, 2025 | 9:15 pm

Roivant Sciences is advancing its drug development through its 'Vant' model, focusing on late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat. The company aims for significant milestones by 2025 and enhances shareholder value through strategic divestitures, such as Dermavant's sale to Organon for $1.2 billion.

Portfolio Pulse from

December 04, 2024 | 1:45 pm

Roivant Sciences Ltd. (ROIV) held its Q2 2024 earnings call, discussing financial performance and company updates.

Portfolio Pulse from

November 12, 2024 | 8:00 pm

Roivant Sciences Ltd. (ROIV) reported a Q2 loss of $0.29 per share, missing the Zacks Consensus Estimate of a $0.21 loss.

Portfolio Pulse from

November 12, 2024 | 2:45 pm

Dermavant presented final data from the ADORING 3 LTE study on VTAMA cream, showing 51.9% of patients achieved complete disease clearance and remained treatment-free for about 80 days. The FDA PDUFA action date is expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.